Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

RVO patients at risk for loss to follow-up after anti-VEGF treatment  Healio

Ocular Surgery News | Despite the proven benefits of anti-VEGF injections for patients with retinal vein occlusion, a retrospective review of billing codes showed ...

Retinal Vein Occlusion Market Set to Record Exponential Growth by 2026  PortNews24

Retinal vein occlusion is blockage of retinal vein due to blood clot. Retinal vein occlusion is the second most common cause of visual impairment globally.

Bilateral central retinal vein occlusion as the first manifestation in chronic myeloid leukaemia  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l685 (Published 21 February 2019) Cite this as: BMJ 2019;364:l685. Article; Related *content*; Metrics; Responses ...

Retinal Vein Occlusion Market Poised to Expand at a Robust Pace by 2026  Market Reporter

Retinal vein occlusion is blockage of retinal vein due to blood clot. Retinal vein occlusion is the second most common cause of visual impairment globally.

Sales Scenario of Global Retinal Vein Occlusion Therapeutics Market to Remain Positive Through 2015-2021  Spaceflight News

Sales Scenario of Global Retinal Vein Occlusion Therapeutics Market to Remain Positive Through 2015-2021 | The Premier Source of Space Exploration and ...

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  Medical Xpress

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the ASR  BioSpace

Published: Jul 27, 2019. Antibody Biopolymer Conjugates are a new scientific approach and design platform for ophthalmic intravitreal drugs; KSI-301 continues ...

Prevalence of resolved paracentral acute middle maculopathy lesions in fellow eyes of patients with unilateral retinal vein occlusion  MD Linx

In this case-control observational study, researchers examined the prevalence of resolved paracentral acute middle maculopathy (PAMM) lesions in fellow eyes ...

A Novel Therapeutic Target for Retinal Vein Occlusion  Technology Networks

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Interesting Sessions to Come at ASRS 2019  MD Magazine

Here's a primer for new data and discussions MD Mag will be covering this weekend in Chicago.

ADM-RAMP2 system could be therapeutic target for retinal vein occlusion  Drug Target Review

Researchers suggest that the retinoprotectivity of the ADM-RAMP2 system makes it an ideal therapeutic target for central retinal vein occlusion (CRVO).

Combined central retinal vein, central retinal artery and cilioretinal | IMCRJ  Dove Medical Press

Combined central retinal vein, central retinal artery and cilioretinal artery occlusion with ischemic macular hole secondary to severe orbital cellulitis after black fly ...

Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Macular Edema Associated With Central Retinal Vein Occlusion in Patients Age 40 Years or Younger  Healio

From Retina *Service*, Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania (XG, AO, CMA, FSA, JFV, JH, ACH);and ...

Retinal Vein Occlusion Market Size and Forecasts Research Report 2019  Industry Stats News

Retinal Vein Occlusion Market research now available at Brand Essence Research encompasses an exhaustive Study of this business space with regards to ...

Central Retinal Vein Occlusion Market Boosting the Growth Worldwide: Central Retinal Vein Occlusion Market Dynamics and Trends, Efficiencies Forecast 2025  Honest Version

Global Central Retinal Vein Occlusion Market Report 2019-2019 – Market Size, Share, Price, Trends and Forecast is a professional and in-depth study on the ...

Regeneron's Eylea snags prefilled syringe approval as Novartis rival looms  FiercePharma

Eye med Eylea has been a blockbuster sales force for Regeneron, but Novartis' challenger brolucizumab is on the horizon. Could a new prefilled syringe ...

Global Retinal Vein Occlusion Market – Premium Insight, Industry Trends, Market Sizing & Forecasts to 2023  Technology Market

Introduction. Retinal vein occlusion is a retinal vascular disease that mainly affects the older population and causes blindness. The condition is basically of two ...

Focus on Eyes: Vision loss and retinal vein occlusion  Florida Today

When a retinal vein is blocked, it can lead to severe loss of vision.

Retinal Vein Occlusion Therapeutics Market 2025 Analysis, Industry Top Manufactures, Market Size, Industry Growth  The Jеnnеr Nеws

Global “Retinal Vein Occlusion Therapeutics Market” provides complete attention on major industry drivers, opportunities, challenges, and their impact on market ...

Treat-and-extend regimen reduces injection burden in macular edema secondary to CRVO  Healio

VIENNA — Intravitreal aflibercept injection with an individualized treat-and-extend schedule is a positive approach to macular edema secondary to central ...

Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?  Yahoo Finance

Regeneron Pharmaceuticals, Inc. REGN is scheduled to release second-quarter 2019 results on Jul 6, before the opening bell. In the last reported quarter, the ...

Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe  Yahoo Finance

Regeneron (REGN) receives FDA approval for a prefilled syringe of its ophthalmology drug, Eylea.

Retinal Vein Occlusion Therapeutics Market Size, Share, Growth, Trends, and Forecast, 2019 to 2023  Rapid News Network

Global Retinal Vein Occlusion Therapeutics Market Report 2019 – Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Global Retinal Vein Occlusion Market 2019 Industry Size, Emerging Technologies, Future Demands, Opportunities, Regional Trends and Industry Growth by Forecast 2023  News In Bites

Global “Retinal Vein Occlusion Market” 2019 Research report provides information regarding market size, share, trends, growth, cost structure, key drivers and ...

Avastin as effective as Eylea for treating central retinal vein occlusion  EurekAlert

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Retinal Vein Occlusion Market Opportunity, Growth, Share, Demand, Innovation, Top Companies – Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers  News Exterior

Retinal Vein Occlusion Market report offers a comprehensive valuation of the marketplace. It does so via in-depth comprehensions, grateful market growth by ...

Treatment arms for CRVO yield no difference in visual acuity results  Healio

BOSTON — Dexamethasone implant, ranibizumab injections or a combination of the two each yielded no statistically significant difference in visual acuity or ...

Central Retinal Vein Occlusion (CRVO)  News-Medical.net

Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back ...

Global Retinal Vein Occlusion Therapeutics Market 2019 – Sanofi Aventis, Valeant Pharmaceuticals, Allergan, … – Honest News 24  Honest News 24

Global Retinal Vein Occlusion Therapeutics Market research report covers the analysis about business overview, market size, share, trends, gross margin, ...

Retinal Vein Occlusion Market Outlook 2019 Witnessing Enormous Growth with Recent Trends & Demand |Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers  Market Research Finance

Retinal Vein Occlusion Market Forecast to 2025. New study on Industrial Growth of Retinal Vein Occlusion Market 2019-2025: The global Retinal Vein Occlusion ...

Bevacizumab as effective as aflibercept for central retinal vein occlusion  The Pharmaceutical Journal

Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Global Retinal Vein Occlusion Market 2019 – Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers  Biz Trends 24

The Retinal Vein Occlusion Market report presents key information on the market status of the key players and is a precious source of direct and plan for ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Shares Acquired by CENTRAL TRUST Co  Mayfield Recorder

CENTRAL TRUST Co raised its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 115.9% in the 2nd quarter, according to the company in its most ...

Retinal Vascular Occlusion (RVO) Market Overview 2019, Global Industry Size, Share, SWOT Analysis, Technology Advancement, Competitive landscape, Regional Forecast to 2023 |  Medgadget

Retinal Vascular Occlusion (RVO) Market Overview Retinal disease burden has continued to rise worldwide, more so among the geriatric population. Many of.

Easier treatment for blinding eye disease shows promise in clinical trial  Science Daily

A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months ...

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

Anti-VEGF Therapy for Retinal Vein Occlusions  Medscape

Is anti-VEGF therapy more effective than the standard of care for retinal vein occlusions? In this video blog, David M. Brown, MD, reflects on the recent BRAVO ...

SCORE2: Visual acuity results with bevacizumab non-inferior to aflibercept as treatment for macular edema due to CRVO  Healio

The SCORE2 study showed that intravitreal bevacizumab is non-inferior to aflibercept as a treatment for macular edema due to central retinal or hemiretinal vein ...

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

VIDEO: SCORE2 and LEAVO trials underway to compare CRVO treatments  Healio

KOLOA, Hawaii ― At Hawaiian Eye 2017, Michael S. Ip, MD, updates colleagues on the U.S.-based SCORE2 trial and the U.K.-based LEAVO trial, both of which ...

CRYSTAL study shows good results of personalized anti-VEGF treatment regimen in CRVO  Healio

Two-year results of the CRYSTAL study show that an as-needed medication regimen with frequent monitoring can reduce the number of anti-VEGF injections ...

FDA OKs Aflibercept (Eylea) for Diabetic Retinopathy  Medscape

The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron) injection solution to treat all stages of diabetic retinopathy, the ...

Should We WAVE Goodbye to Laser?  Medscape

This study helps answer a common clinical question as to whether peripheral laser to areas of retinal ischemia improves vision and reduces injection burden in ...

Case Report Highlights Acute Central Retinal Vein Occlusion in Scleroderma Patient  Scleroderma News

Researchers in Saudi Arabia at King Fahd Hospital of the University and the University of Dammam reported a case of a male patient with scleroderma who was ...

Recon: Pfizer to Merge Off-Patent Drug Business With Mylan  Regulatory Focus

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. Pfizer to Merge Its Off-Patent Drug Unit With Mylan ...

HSBC Life launches critical illness plans - CIExpert analysis | COVER  COVER

After entering the advised space with a life assurance proposition last year, HSBC Life has followed it with the launch of two critical illness products - critical ...

Ocular Diagnostic Agents Market Poised to Garner Maximum Revenues by 2026  PortNews24

Eye is the most accessible organ in the human body. Due to this feature, ophthalmic diagnostics agents play a significant role in ophthalmology to aid effective ...

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

THERAPIX BIOSCI/S (NASDAQ:TRPX) vs. Regeneron Pharmaceuticals (NASDAQ:REGN) Head to Head Comparison  Mayfield Recorder

THERAPIX BIOSCI/S (NASDAQ:TRPX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better investment?

Cheap Avastin as effective as Eylea in CRVO  European Biotechnology

A study conducted by an NIH institute proves Roche's Avastin is as effective as Regeneron's Eylea, a drug that costs 30 times more than Roche's antibody.

Eylea Market Share 2x more Than Lucentis in WMD and 3x more in DME/DR based on Medicare Claims Analysis  Dexur

Dexur's analysis of medicare claims shows that Eylea (Aflibercept) is being used twice as much as Lucentis (Ranibizumab) for Wet Age-related Macular ...

Ozurdex for retinal vein occlusion available in China  Healio

Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, ...

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

Retinal artery and vein thrombotic occlusion during pregnancy: markers | OPTH  Dove Medical Press

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes Will S Kurtz,1 Charles J ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Central retinal vein occlusion (CRVO): Types, causes, symptoms, and treatment  Bel Marra Health

Central retinal vein occlusion (CRVO) refers to a medical condition of the eye where main vein of the retina has become blocked.

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

CRAO and Stroke Risk: Is Neurological Evaluation Warranted?  Medscape

Patients with central retinal artery occlusion may be at an increased risk for stroke and may benefit from prompt neurological evaluation, according to a new ...

Retinal Findings in Young Children With Increased Intracranial Pressure From Nontraumatic Causes  AAP News

OBJECTIVES: Increased intracranial pressure (ICP) has been suggested in legal settings as an alternative cause of retinal hemorrhages (RHs) in young ...

BRVO: Bevacizumab and Ranibizumab Both Effective  Medscape

Patients with branch retinal vein occlusion (BRVO) who have been treated with either bevacizumab or ranibizumab experienced significant gain in visual acuity.

Three trials show efficacy of suprachoroidal CLS-TA injections for macular edema in uveitis  Healio

FORT LAUDERDALE, Fla. — Three clinical trials demonstrated rapid and sustained reduction of macular edema secondary to noninfectious uveitis in patients ...

FDA accepts Clearside's NDA for Xipere suprachoroidal injection  Healio

The FDA has accepted a new drug application for Xipere suprachoroidal injection for the treatment of macular edema associated with uveitis, according to a ...

BB&T Corp Increases Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Mayfield Recorder

BB&T Corp grew its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.6% in the 2nd quarter, according to the company in its most ...

Boston Advisors LLC Has $268,000 Stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Mayfield Recorder

Boston Advisors LLC lowered its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 92.6% during the second quarter, according to its most recent ...

Double-Barreled Biologic for Diabetic Retinopathy Emerging  Medscape

Trial results for the first biologic to target both the VEGF and Ang-2 pathways designed for less frequent injections than current options will be presented at the ...

Similar Efficacy for Key Anti-VEGF Agents in Macular Edema  Medscape

The SCORE2 trial shows that bevacizumab and aflibercept may produce similar short-term outcomes. Here is a closer look at its results.

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Kindred Biosciences (NASDAQ:KIN) and Regeneron Pharmaceuticals (NASDAQ:REGN) Financial Review  Tech Know Bits

Regeneron Pharmaceuticals (NASDAQ:REGN) and Kindred Biosciences (NASDAQ:KIN) are both medical companies, but which is the better stock? We will ...

Monthly, PRN doses of ranibizumab similarly effective in RVO  Healio

TORONTO — As-needed and monthly ranibizumab dosing regimens yielded similar visual acuity gains in patients with retinal vein occlusion who reached a ...

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Short Interest Update  Mayfield Recorder

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest ...

Essay: Mom sees life from the sunny side  Newsday

Five days before Christmas 2016, my vivacious, bubbly, loving mother, Vivian Schachter, suddenly lost most of her vision. She had central retinal vein occlusion.

TMR : Central Retinal Vein Occlusion Global Clinical Trials Review, H2, 2018 Research Offer by The Market Reports  Premier Herald

This report provides top line data relating to the clinical trials on Central Retinal Vein Occlusion. Report includes an overview of trial numbers and their average ...

BLOG: Laser still has an important role in diabetic eye disease  Healio

Ophthalmology Blogs | Mali | There is no question that the introduction of anti-VEGF agents has dramatically changed the landscape of how surgeons approach ...

New gene therapy for vision loss proven safe in humans  Medical Xpress

In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Sees Significant Increase in Short Interest  Mayfield Recorder

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was ...

High Blood Pressure, High Cholesterol May Be Associated With Retinal Vascular Disease  Science Daily (press release)

High blood pressure and high cholesterol levels appear to be risk factors for retinal vein occlusion, a condition that causes vision loss, according to a new article.

Retinal Vein Occlusion Market Global Industry Analysis, Size, Share, Growth, Trends, And Forecast, 2016 To 2022  Market Reporter

Retinal vein occlusion is a retinal vascular disease that mainly affects the older population and causes blindness. The condition is basically of two types, namely, ...

Global Cystoid Macular Edema Market 2019 Global Industry Size, Share, Revenue, Business Growth, Demand and Applications Market Research Report to 2025  The Rent Fint

A defined analysis of the existing state of the “Cystoid Macular Edema Market” is done on this market research report. The document consists of evaluation of ...

Hartford Investment Management Co. Grows Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Mayfield Recorder

Hartford Investment Management Co. lifted its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.8% during the 2nd quarter, according to its most ...

Bayer files eye drug Eylea for new use in EU  PMLiVE

Bayer has filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion ...

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)  PR Newswire

DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food ...

NICE backs Bayer's Eylea as first-line BRVO treatment  PMLiVE

Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein ...

Vascular Endothelial Growth Factor B Market Revenue, Status and Outlook 2018 to 2025  Newzy

The Vascular Endothelial Growth Factor B Market Size, Status And Forecast 2019-2025. The report provides information and the advancing Vascular Endothelial ...

TANZANITE study: No re-treatments required with triamcinolone acetonide formulation after 3 months  Healio

A majority of patients treated with a proprietary form of triamcinolone acetonide in combination with aflibercept required no additional treatments over 3 months ...

Regeneron (REGN) to Report Q1 Earnings: What's in Store?  Yahoo Finance

Regeneron Pharmaceuticals, Inc. REGN is scheduled to release first-quarter 2019 results on May 7, before the opening bell. In the last reported quarter, the ...

MEK Inhibitors Linked to Ocular Adverse Effects  Medscape

MEK inhibitors appear to be associated with a risk for ocular side effects, and patients should be monitored.

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Watchful waiting reasonable for patients with diabetic macular edema and good vision  Medical Xpress

People with good vision despite having center-involved diabetic macular edema can safely forego immediate treatment of their eye condition as long as they are ...

Sustained delivery system intended to ease AMD treatment burden  Healio

A new port delivery system may secure sustained, long-term release of anti-VEGF in patients with wet age-related macular degeneration, easing the burden of ...

Roche reports very strong performance in the first half of 2019 – Outlook raised  GlobeNewswire

Basel, 25 July 2019. Group sales increase 9%1 at constant exchange rates and 8% in Swiss francs; Pharmaceuticals Division sales up 10%, driven mainly by ...

Cornerstone Advisors Inc. Sells 51 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Slater Sentinel

Cornerstone Advisors Inc. reduced its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 6.1% during the second quarter, according to the ...

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-m | OPTH  Dove Medical Press

Tetsuya Muto, Shigeki Machida Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan Purpose: To determine ...

A Girl Whose Eyes Appear White in Photos  Medscape

A 6-year-old girl was referred to pediatric ophthalmology for a white reflex that was seen in photographs by her parents. Initially, the mother only saw the white ...

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)  BioSpace

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study ...

» Load more